PharmaNet Development Group is collaborating with the Cancer Immunotherapy Trials Network (CITN) to help identify trials with immunotherapy agents prioritized by CITN as having high potential for cancer therapy. PharmaNet will focus its expertise in the development of immunotherapies and cancer vaccines to support this initiative. “We are thrilled to collaborate with the CITN multi-investigator team,” said PharmaNet’s Dr. Anthony Maida, vice president, Clinical Research and general manager, O...